CVS Health’s CVS Pharmacy and Consumer Wellness (“PCW”) segment has seen steady growth in recent months, with revenues up 11.1% year over year in the first quarter of 2025.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...

Current parameters surrounding CVS Health represent a biased reward/risk ratio. Click here to see why I upgraded my rating of ...

CVS Health reported Q4 revenue of $97.71B, surpassing the $97.19B consensus. 2025 revenue is expected to exceed $134B, driven by higher prescription volumes. Historic Summer Setup: 3 "Power ...

CVS Health (CVS) stock gains as company reports better than expected Q3 2024 ... CVS' Pharmacy & Consumer Wellness segment added $32.4B in revenue with ~12% YoY growth as prescriptions filled ...

CVS Health’s CVS Pharmacy and Consumer Wellness (“PCW”) segment has seen steady growth in recent months, with revenues up 11.1% year over year in the first quarter of 2025. Performance was supported ...

Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026 ...